Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 14:08 save search
Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
Published: 2021-01-13 (Crawled : 13:08) - jaguarhealth.gcs-web.com
JAGX | $0.1767 48.74% 430M
|
Health Technology
|
| O: 13.61%
H: 2.34%
C: -3.91%
disease tropical disease
Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from
Published: 2021-01-06 (Crawled : 14:08) - jaguarhealth.gcs-web.com
JAGX | $0.1767 48.74% 430M
|
Health Technology
|
| O: 4.62%
H: 12.75%
C: -1.47%
disease drug diarrhea infectious disease preclinical pre-clinical
Gainers vs Losers
| 51% | 49% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.